Kara Hart, NP
Nurse Practitioner · Pueblo, CONPI 1073878617
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,830 of the $141,886 with a category attached, or 73.2%. AstraZeneca accounts for 65.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $72,778 and has fallen 99.7% since, to $216 in 2025. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $496.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$94K
- GSK$30K
- Amgen$15K
- Seagen Inc.$702
- Pfizer$540
- Johnson & Johnson$423
- plus $2K from 17 others
What the payments were for
- Consulting fees$7,7355%
- Speaking & faculty fees$103,83073%
- Travel & lodging$23,31416%
- Food & beverage$6,4945%
- Education$5130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 148 | $93,564 |
| GSK | 47 | $29,622 |
| Amgen | 44 | $15,271 |
| Seagen Inc. | 7 | $702 |
| Pfizer | 1 | $540 |
| Johnson & Johnson | 5 | $423 |
| E.r. Squibb & Sons, L.L.C. | 6 | $365 |
| Gilead | 8 | $210 |
| Bayer | 3 | $138 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Apellis Pharmaceuticals, Inc. | 1 | $124 |
| Legend Biotech USA Inc. | 1 | $91 |
| Exelixis Inc. | 1 | $83 |
| Genentech USA, Inc. | 1 | $72 |
| AVEO Pharmaceuticals, Inc. | 1 | $70 |
| Bristol Myers Squibb | 3 | $64 |
| Tempus AI, Inc | 1 | $54 |
| Novartis | 1 | $45 |
| Novocure Inc. | 2 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,886 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 24 | $387,726 |
| ImbruvicaIbrutinib | 26 | $313,203 |
| RevlimidLenalidomide | 14 | $275,696 |
| XtandiEnzalutamide | 19 | $261,515 |
| IbrancePalbociclib | 12 | $196,583 |
| CalquenceAcalabrutinib Maleate | 13 | $177,042 |
| XareltoRivaroxaban | 26 | $26,109 |
| EliquisApixaban | 20 | $15,162 |
| Anastrozole | 147 | $2,812 |
| Exemestane | 41 | $2,497 |
| Oxycodone Hcl | 78 | $2,008 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $1,468 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 34 | $1,189 |
| Morphine Sulfate ErMorphine Sulfate | 33 | $1,165 |
| Hydroxyurea | 26 | $1,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $313,20326 claims |
| Bristol Myers SquibbRevlimid | $64 | $275,69614 claims |
| PfizerIbrance, Eliquis | $540 | $211,74532 claims |
| AstraZenecaCalquence | $93,564 | $177,04213 claims |
| Johnson & JohnsonXarelto | $423 | $26,10926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Pueblo
- Karen SpringfieldPueblo$5K
- Linda JacksonPueblo$5K
- Deborah HinnenColorado Springs$388K
- Christina HansonLone Tree$381K
- Amy SidorskiAurora$97K
- Lori WenzGrand Junction$54K
- Lisa KeithColorado Springs$52K
- Victoria SegroEnglewood$29K
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.